J
Jaap Wals
Publications - 4
Citations - 1055
Jaap Wals is an academic researcher. The author has contributed to research in topics: Performance status & Capecitabine. The author has an hindex of 4, co-authored 4 publications receiving 953 citations.
Papers
More filters
Journal ArticleDOI
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Miriam Koopman,Ninja Antonini,Joep Douma,Jaap Wals,Aafke H. Honkoop,Frans L. G. Erdkamp,Robert S. de Jong,C.J. Rodenburg,Gerard Vreugdenhil,Olaf J. L. Loosveld,Aart van Bochove,Harm Sinnige,Geert-Jan Creemers,Margot E T Tesselaar,Peter H. Th J. Slee,Marjon J. B. P. Werter,Linda Mol,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: Combination treatment does not significantly improve overall survival compared with the sequential use of cytotoxic drugs in advanced colorectal cancer, and sequential treatment remains a valid option for patients with advanced coloresceptic cancer.
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study
Frank P.J. Peters,Roy I. Lalisang,Martin M.F. Fickers,Frans L. G. Erdkamp,Jacq A.J.M. Wils,Sjef G.J. Houben,Jaap Wals,Harrie C. Schouten +7 more
TL;DR: A significant subset (76.5%) of elderly people with intermediate/high-grade NHL received suboptimal therapy, mainly because of aSuboptimal performance status, which cannot be explained by the different international prognostic index.
Journal ArticleDOI
The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates
TL;DR: The combination of CHOP plus G-CSF increased the absolute number of treatable elderly patients, resulting in more patients with complete remission and overall survival compared to the previous study.